Travere Therapeutics, Up 106% In 2025, ‘Shrugs Off’ Competition In Hot Kidney Space

Travere Therapeutics (TVTX) stock has more than doubled in 2025 even as competition heats up for its bread-and-butter drug, Filspari. Wall Street analysts say the company still has room to run. Filspari is approved to treat patients with IgA nephropathy, or IgAN. In this condition, abnormal antibodies build up in the kidneys’ filtering units, causing inflammation and damage. The Food…